RecruitingPhase 1NCT06378957

Behavioral Pharmacology of Orally Administered THC and D-limonene

Sponsor

Johns Hopkins University

Enrollment

65 participants

Start Date

Feb 14, 2025

Study Type

INTERVENTIONAL

Conditions

THC Subjective Drug Effects D-limonene

Summary

The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.

Eligibility

Min Age: 21 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called D-Limonene, a drug called Delta-9-THC, and others for people with d-limonene, subjective drug effects, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGD-Limonene

Oral Limonene administered via capsule

DRUGDelta-9-THC

Oral delta-9-THC in ethanol vehicle administered via capsule

DRUGPlacebo

Placebo (cellulose) administered via capsule

Locations(1)

Johns Hopkins Behavioral Pharmacology Research Unit

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06378957

Related Trials

THC Titration of High-Potency Cannabis Concentrates

NCT071054491 location

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

NCT055148991 location